ARK Genomic Revolution ETF vs Abrdn Physical Platinum Shares ETF — how do they compare? ARK Genomic Revolution ETF trades at $44.53, while Abrdn Physical Platinum Shares ETF trades at $16. The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals.
| ARKG | PPLT | |
|---|---|---|
Sector | Sector/Thematic | Commodities - Metals/Agriculture |
52-Week High | $44.55 | $25.23 |
52-Week Low | $24.02 | $11.95 |
Signals from Pluang's Aura AI — not financial advice
ARKG, the ARK Genomic Revolution ETF, trades at $43.04, up 6.06% in the past 24 hours, with a bullish technical signal from moving averages and ADX indicators. The ETF focuses on small- and mid-cap biotech stocks, with its top 10 holdings comprising 59% of the portfolio and a long-term EPS growth rate of 10.7%. Recent news highlights its recovery from a 15% correction, with support emerging at key levels.
The outlook for ARKG is positive, driven by biotech sector tailwinds including a friendlier FDA, strong M&A activity, and AI-driven drug discovery. Risks include high concentration in volatile biotech names and sensitivity to broader market sell-offs. Investors should weigh the growth potential against the inherent volatility of genomics investments.
PPLT trades at $15.85, up 1.15% today, with a bullish technical signal from moving averages but a neutral reading from oscillators. The stock is set for a 1:10 stock split effective May 18, 2026. Recent news highlights platinum's underperformance versus gold and silver, positioning PPLT as a potential catch-up trade in the precious metals sector.
The outlook for PPLT hinges on a potential rebound in platinum prices, supported by positive sentiment from recent geopolitical developments. Key risks include continued commodity price volatility and the ETF's lack of dividend income, which may deter yield-seeking investors despite its strong past performance.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →